Immunomodulatory action of intravenous immunoglobulin

Immunology

Volumn 107, Issue 4, 2002, Pages 387-393

  Sewell, W A C ^a   Jolles, S ^b,c  

^a SCUNTHORPE GENERAL HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MALTOSE; SUCROSE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; ANTIBODY; COMPLEMENT RECEPTOR; FC RECEPTOR; GLUCOCORTICOID RECEPTOR;

ANTIBODY TITER; APOPTOSIS; ASTHMA; AUTOIMMUNE DISEASE; BINDING SITE; CELL ADHESION; CELL CYCLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG MANUFACTURE; EPILEPSY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; CELL DIVISION; CYTOLOGY; IMMUNOLOGY; PHAGOCYTOSIS; T LYMPHOCYTE;

ANTIBODIES; APOPTOSIS; CELL CYCLE; CELL DIVISION; CYTOKINES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; PHAGOCYTOSIS; RECEPTORS, COMPLEMENT; RECEPTORS, FC; RECEPTORS, GLUCOCORTICOID; T-LYMPHOCYTES;

EID: 0036884344     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2002.01545.x     Document Type: Review

References (65)

1. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-31.
2. Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001; 26:127-31.
3. Kawada K, Terasaki PI. Evidence for immunosuppression by high-dose gammaglobulin. Exp Hematol 1987; 15:133-6.
4. Klaesson S, Ringden O, Markling L, Remberger M, Lundkvist I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol 1993; 38:477-84.
5. van Schaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992; 12:325-34.
6. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73:180-6.
7. Stohl W, Cunningham-Rundles C, Thompson C, Mayer L. Modulation of the immune response by immunoglobulin for intravenous use. II. Inhibitory effects of sera from treated patients. Clin Immunol Immunopathol 1986; 41:273-80.
8. Ballow M, White W, Desbonnet C. Modulation of in vitro synthesis of immunoglobulin and the induction of suppressor activity by therapy with intravenous immune globulin. J Allergy Clin Immunol 1989; 84:595-601.
9. Aktas O, Waiczies S, Grieger U, Wendling U, Zschenderlein R, Zipp F. Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto) antigen-specific T cells without inducing apoptosis. J Neuroimmunol 2001; 114:160-7.
10. Ekberg C, Nordstrom E, Skansen-Saphir U, Mansouri M, Raqib R, Sundqvist VA, Fernandez C. Human polyspecific immunoglobulin for therapeutic use induces p21/WAF-1 and Bcl-2, which may be responsible for G1 arrest and long-term survival. Hum Immunol 2001; 62:215-27.
11. van Schaik IN, Vermeulen M, Brand A. In vitro effects of polyvalent immunoglobulin for intravenous use. J Neurol Neurosurg Psychiatr 1994; 57 (Suppl. 15): 15-7.
12. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV. Therapeutic preparations of normal poly-specific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161:3781-90.
13. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-3.
14. Trautmann A, Akdis M, Schmid-Grendelmeier P, Disch R, Brocker EB, Blaser K, Akdis CA. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001; 108:839-46.
15. Osei A, Uttenreuther-Fischer MM, Lerch H, Gaedicke G, Fischer P. Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin. Arthritis Rheum 2000; 43:2722-32.
16. Leucht S, Uttenreuther-Fischer MM, Gaedicke G, Fischer P. The B cell superantigen-like interaction of intravenous immunoglobin (IVIg) with Fab fragments of V (H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIg therapy. Clin Immunol 2001; 99:18-29.
17. Teeling JL, Bleeker WK, Rigter GM, van Rooijen N, Kuijpers TW, Hack CE. Intravenous immunoglobulin presss induce mild activation of neutrophils in vivo via triggering of macrophages - studies in a rat model. Br J Haematol 2001; 112:1031-40.
18. Zhuang Q, Mazer B. Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin. J Allergy Clin Immunol 2001; 108:229-34.
19. Jerzak M, Rechberger T, Gorski A. Intravenous immunoglobulin therapy influences T cell adhesion to extracellular matrix in women with a history of recurrent spontaneous abortions. Am J Reprod Immunol 2000; 44:336-41.
20. Huang JL, Lee WY, Chen LC, Kuo ML, Hsieh KH. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2000; 84:345-52.
21. Vassilev TL, Kazatchkine MD, Van Huyen JP et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999; 93:3624-31.
22. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. J Clin Invest 1993; 91:602-7.
23. Lamari F, Anastassiou ED, Tsegenidis T, Dimitracopoulos G, Karamanos NK. An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin presss and blood serum. J Pharm Biomed Anal 1999; 20:913-20.
24. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110:135-49.
25. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspeciflc Ig. J Immunol 1989; 143:4104-9.
26. Ronda N, Haury M, Nobrega A, Coutinho A, Kazatchkine MD. Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopathol 1994; 70:124-8.
27. Ronda N, Haury M, Nobrega A, Kaveri SV, Coutinho A, Kazatchkine MD. Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus. Int Immunol 1994; 6:1651-60.
28. Rossi F, Dietrich G, Kazatchkine M. [Anti-idiotype suppression of autoimmunity by therapeutic intravenous immunoglobulins]. Ann Med Interne 1988; 139:359-68.
29. Abe Y, Miyake M, Sagawa T, Kimura S. Enzyme-linked immunosorbent assay (ELISA) for human tumor necrosis factor (hTNF). Clin Chim Acta 1988; 176:213-7.
30. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139:5-19.
31. Reitamo S, Remitz A, Varga J, Ceska M, Effenberger F, Jimenez S, Uitto J. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders. Arch Dermatol 1993; 129:189-93.
32. Toungouz M, Denys CH, De Groote D, Dupont E. In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 1995; 89:698-703.
33. Denys C, Toungouz M, Dupont E. Increased in vitro immunosuppressive action of anti-CMV and anti-HBs intravenous immunoglobulins due to higher amounts of interferon-gamma specific neutralizing antibodies. Vox Sang 1997; 72:247-50.
34. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992; 89:3325-9.
35. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993; 92:369-72.
36. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, Kazatchkine MD. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1994; 1:269-77.
37. Iwata M, Shimozato T, Tokiwa H, Tsubura E. Antipyretic activity of a human immunoglobulin press for intravenous use in an experimental model of fever in rabbits. Infect Immun 1987; 55:547-54.
38. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71:372-6.
39. Ruiz de Souza V, Carreno MP, Kaveri SV et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995; 25:1267-73.
40. Andersson UG, Bjork L, Skansen-Saphir U, Andersson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79:211-6.
41. Andersson U, Bjork L, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21-42.
42. Ling ZD, Yeoh E, Webb BT, Farrell K, Doucette J, Matheson DS. Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo. J Clin Immunol 1993; 13:302-9.
43. Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, Espevik T. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-43.
44. Farber CM, Crusiaux A, Schandene L, van Vooren JP, Goldman M, Dupont E, Tasiaux N. Tumor necrosis factor and intravenous gammaglobulins in common variable immunodeficiency. Clin Immunol Immunopathol 1994; 72:233-6.
45. Aukrust P, Hestdal K, Lien E, Bjerkeli V, Nordoy I, Espevik T, Muller F, Froland SS. Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-alpha activity in human immunodeficiency virus type 1 infection. J Infect Dis 1997; 176:913-23.
46. Sewell WA, North ME, Cambronero R, Webster AD, Farrant J. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol 1999; 116:509-15.
47. Aspalter RM, Sewell WA, Dolman K, Farrant J, Webster AD. Deficiency in circulating natural killer (NK) cell subsets in common variable immunodeficiency and X-linked agammaglobulinaemia. Clin Exp Immunol 2000; 121:506-14.
48. Cambronero R, Sewell WA, North ME, Webster AD, Farrant J. Up-regulation of IL-12 in monocytes: a fundamental defect in common variable immunodeficiency. J Immunol 2000; 164:488-94.
49. Bhol KC, Desai A, Kumari S, Colon JE, Ahmed AR. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. Clin Immunol 2001; 100:172-80.
50. Schwaighofer H, Oberhuber G, Hebart H et al. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy. Transplantation 1997; 63:52-6.
51. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254-8.
52. Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 1984; 132:745-50.
53. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986; 314:1236-9.
54. Clarkson SB, Kimberly RP, Valinsky JE, Witmer MD, Bussel JB, Nachman RL, Unkeless JC. Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med 1986; 164:474-89.
55. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIg mediated through the inhibitory Fc receptor. Science 2001; 291:484-6.
56. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2000; 18:739-66.
57. Diegel ML, Rankin BM, Bolen JB, Dubois PM, Kiener PA. Cross-linking of Fc gamma receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem 1994; 269:11409-16.
58. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6:683-9.
59. Spahn JD, Leung DY, Chan MT, Szefler SJ, Gelfand EW. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol 1999; 103:421-6.
60. Basta M, Langlois PF, Marques M, Frank MM, Fries LF. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989; 74:326-33.
61. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134:80-6.
62. Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001; 124:282-9.
63. Lain L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342:678.
64. Alder LB, Morgan LA, Spickett GP. Contribution of stabilizing agents present in intravenous immunoglobulin presss to modulation of mononuclear cell proliferation in vitro. Scand J Immunol 1996; 44:585-91.
65. Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor beta. Lancet 1998; 351:184-5.